Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$7.25 - $10.99 $1.57 Million - $2.37 Million
-216,100 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$4.57 - $11.18 $90,677 - $221,833
-19,842 Reduced 8.41%
216,100 $2.12 Million
Q4 2020

Feb 02, 2021

SELL
$3.73 - $5.6 $16,785 - $25,200
-4,500 Reduced 1.87%
235,942 $1.05 Million
Q3 2020

Nov 05, 2020

BUY
$4.32 - $11.7 $238,999 - $647,290
55,324 Added 29.89%
240,442 $1.04 Million
Q2 2020

Aug 12, 2020

BUY
$2.94 - $9.1 $44,740 - $138,483
15,218 Added 8.96%
185,118 $1.64 Million
Q1 2020

May 12, 2020

BUY
$2.27 - $6.2 $53,345 - $145,700
23,500 Added 16.05%
169,900 $600,000
Q4 2019

Jan 27, 2020

BUY
$3.46 - $6.93 $299,636 - $600,138
86,600 Added 144.82%
146,400 $837,000
Q3 2019

Oct 31, 2019

BUY
$2.69 - $4.85 $38,198 - $68,870
14,200 Added 31.14%
59,800 $214,000
Q2 2019

Aug 15, 2019

SELL
$3.65 - $7.89 $13,505 - $29,193
-3,700 Reduced 7.51%
45,600 $182,000
Q1 2019

May 03, 2019

SELL
$7.08 - $12.09 $9,204 - $15,717
-1,300 Reduced 2.57%
49,300 $360,000
Q4 2018

Feb 08, 2019

SELL
$8.14 - $13.28 $20,350 - $33,200
-2,500 Reduced 4.71%
50,600 $463,000
Q3 2018

Nov 13, 2018

SELL
$11.85 - $16.0 $205,870 - $277,968
-17,373 Reduced 24.65%
53,100 $658,000
Q2 2018

Aug 15, 2018

SELL
$15.15 - $20.75 $199,374 - $273,070
-13,160 Reduced 15.74%
70,473 $1.08 Million
Q1 2018

May 11, 2018

BUY
$14.65 - $19.9 $769,784 - $1.05 Million
52,545 Added 169.02%
83,633 $1.66 Million
Q4 2017

Feb 06, 2018

BUY
$17.3 - $24.08 $319,842 - $445,191
18,488 Added 146.73%
31,088 $581,000
Q3 2017

Nov 15, 2017

BUY
$15.2 - $21.5 $191,520 - $270,900
12,600
12,600 $271,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.74B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.